In a world first, an Australian doctor has completed the first human clinical trial using engineered stem cells to treat an immune disease.
The trial used induced pluripotent stem cells to treat 15 patients in Australia and the UK with an immune disorder called graft versus host disease.
The disease can occur after a bone marrow transplant and, in some cases, can be deadly.
Professor John Rasko has led a world-first human clinical trial using reprogammed stem cells to treat an immune disorder called graft versus host disease.Credit:Wolter Peeters
Royal Prince Alfred Hospital head of Cell and Molecular Therapies Professor John Rasko AO said graft versus host patients could develop severe gut symptoms, or in their skin or lungs.
"It's an immune attack and the cells that I'm now talking about, derived from these reprogrammed cells, are capable of suppressing that kind of an immune response," he said.
Professor Rasko said the early phase clinical study with a small number of patients, published in Nature Medicine, showed promise.
Induced pluripotent stem (iPS) cell used in stem cell research.Credit:Australian Stem Cell Centre
"None of these patients had any complications that were of any significance," he said.
While embryonic stem cells come with ethical concerns for some members of the community, and adult stem cells come from different donors which can lead to varying results or problems, Professor Rasko said these reprogrammed cells can be grown in an "unlimited supply".
"We were able to grow these cells indefinitely in an unlimited amount, and produce them safely and then check them and make sure they're safe," he said. "There's no other technology that can do this."
Rebecca Rudy was diagnosed with leukemia in 2018 and as part of her treatment at St Vincent's Hospital, with haematologist Professor Sam Milliken, received a stem cell transplant last year. Two months later, she developed graft versus host disease.
The research shows promise for people suffering from immune diseases. Credit:Louise Kennerley
"I felt really good. And then all of a sudden, I started to get really, really bad cramps and contractions in the stomach like I was giving birth, that bad," she said.
"I basically had to come into hospital, get morphine injections, and then be hospitalised for a week or two weeks while they upped my steroids and other medication till I was well enough to go home again."
Ms Ruby said since that initial onset in April, she's had four "excruciating" bouts of the disease. While the disease is now "niggling", Ms Ruby said she will have to stay on steroids indefinitely until it's under control.
Feeling fantastic at the moment, Ms Ruby said Professor Milliken's treatment saved her life, and she was not part of Professor Rasko's trial. However she said it would "amazing" if Professor Rasko's treatment could prevent others going through the same experience with graft versus host disease.
"It's something people wouldn't want to go through, I can assure you," she said.
Professor Sam Milliken, who is head of the department of Haematology at St Vincent's, said the study looked promising, particularly for the production of large numbers of these cells. However the small number of patients meant further work needed to be done, he said.
"If you've only got 15 patients in this study, chance can play a much bigger role than if you have 500 people in the study," he said.
Professor Milliken said it would be important to see these results replicated in larger, randomised trials to make sure the reprogrammed cells were the thing that made the difference.
"I don't want to downplay it, it's a very good result, but it needs to be confirmed with some bigger studies," he said.
Progress on treatments with these induced pluripotent stem cells has been limited so far, predominantly due to technical hurdles. Professor Rasko said through this trial, with medicine company Cynata, they've hopefully shown those hurdles can be overcome.
"Now we've set the scene for using these cells to give rise, for example, to bone cells where we can treat people who have fractures which aren't repairing, or people who need a new kidney, potentially," Professor Rasko said.
"Ultimately, we dream of the day where we will be able to regenerate human tissues, and this is the first little step in that direction."
Get our Morning & Evening Edition newsletters
The most important news, analysis and insights delivered to your inbox at the start and end of each day. Sign up to The Sydney Morning Herald’s newsletter here, to The Age’s newsletter here and Brisbane Times‘ here.
Most Viewed in National
Source: Read Full Article